Skip to main content
. 2021 Nov 12;11(11):1192. doi: 10.3390/jpm11111192
COVID-19 Coronavirus-induced disease 2019
CPIC Clinical Pharmacogenetics Implementation Consortium
DDI Drug–drug interaction
FDA U.S. Food and Drug Administration
HCC Hierarchical conditions category
LOS Length of stay
PIP Pharmacogenetic interaction probability
RAF Risk adjustment factor
SNP Special needs plan